Caribou Biosciences(CRBU)

BERKELEY, CABiotechnology2 H-1B visas (FY2023)

Focus: Caribou Biosciences is a public biotech company specializing in cellular engineering tools based on CRISPR gene-editing technology, focused on developing allogeneic CAR-T cell therapies for hematologic and oncologic indications. The company operates as a mid-cap biotech platform with early-stage pipeline assets.

Gene Therapy

Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

5+1 this month

Stable — net +1 jobs in 30d

3 added, 2 removed. Backfill posture.

Should You Work at Caribou Biosciences?

AI assessment

Caribou offers frontier CRISPR science and public-company credibility, but severe cash depletion, early-stage pipeline, and reduced hiring create material restructuring risk for career continuity.

Why Work Here

Cutting-edge CRISPR platform technology with foundational IP in cellular engineering attracts scientists pursuing next-generation gene therapy

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$10M

Pipeline & Clinical Trials

Caribou-sponsored investigational therapy

Lymphoma, Non-Hodgkin

N/A

Clinical Trials (1)

NCT05332054Long-Term Follow-up Study

N/A

Help build intelligence for Caribou Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status (NASDAQ: CRBU) provides equity upside potential and career stability versus pre-revenue private startups

Early-stage pipeline across multiple hematologic cancers (NHL, multiple myeloma, AML) and autoimmune disease (SLE) offers broad technical exposure

Watch Out For

Severe cash burn: FY2025 R&D spend ($130M) is 1,300% of revenue ($10M), with only $16M cash remaining—runway concerns are acute
Early-stage pipeline with zero Phase 2+ programs; all 5 programs are Phase 1, indicating 7–10+ years before potential first approval
Minimal hiring (3 open roles) and declining headcount signals suggest belt-tightening; FY2025 revenue dropped 71% YoY ($34M→$10M)

Generated by Claude from Caribou Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

CB-010

Lymphoma, Non-Hodgkin

PHASE_1

Clinical Trials (1)

NCT04637763CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Phase 1

CB-011

Relapsed/Refractory Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT05722418CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

CB-012

Acute Myeloid Leukemia, in Relapse

PHASE_1

Clinical Trials (1)

NCT06128044CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

CB-010

Systemic Lupus Erythematosus

PHASE_1

Clinical Trials (1)

NCT06752876CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

Phase 1

Interview Prep Quick Facts

Founded: 2015

Portfolio: 5 clinical trials

Top TAs: Oncology, Immunology

H-1B (2023): 2 approvals

Publications: 20 in PubMed

SEC Filings: 2 available

Open Roles: 5 active jobs

Therapeutic Area Focus

Oncology

4 pipeline

Immunology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$10M71%

R&D Spend

$130M(1302%)16%

Net Income

-$149M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Identifying the genetic basis and molecular mechanisms underlying phenotypic correlation between complex human traits using a gene-based approach.

bioRxiv : the preprint server for biology

2025

PMID:40777445

High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.

Cancer immunology research

2024

PMID:38345397

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Caribou Biosciences(CRBU)

Should You Work at Caribou Biosciences?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Caribou Biosciences(10)

Open Jobs (5)

Medical Director

Senior Medical Science Liaison (Senior MSL) or Field Medical Affairs Director

Senior Manager of Clinical Biomarkers

Clinical Trial Manager

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Research Publications(10)